Prescribing Information See
Found 9 free book(s)
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.gene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ESBRIET safely and effectively. See full prescribing information for ESBRIET. • ESBRIET. ESBRIET® (pirfenidone) capsules and film-coated tablets, for oral use Initial U.S. Approval: 2014 discontinuations may be required.
HIGHLIGHTS OF PRESCRIBING INFORMATION thereafter or …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.merck.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) tablets, for oral use Initial U.S. Approval: 2006-----INDICATIONS AND USAGE members -----
HIGHLIGHTS OF PRESCRIBING INFORMATION or after …
www.rxabbvie.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA. VENCLEXTA® (venetoclax tablets), for oral use Initial U.S. Approval: 2016 INDICATIONS AND USAGE VENCLEXTA is a BCL-2 inhibitor indicated:
HIGHLIGHTS OF PRESCRIBING INFORMATION Before …
docs.boehringer-ingelheim.comSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 6/2021 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Prior to Initiation of JARDIANCE 2.2 Recommended Dosage 2.3 Dosage Recommendations in Patients with Renal Impairment 3 DOSAGE FORMS AND STRENGTHS 4 …
DOSAGE FORMS AND STRENGTHS See full prescribing ...
www.austedo.comSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 6/2021 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON’S DISEASE 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information 2.2 Switching Patients from …
See full prescribing information for complete boxed ...
labeling.bayerhealthcare.comSee full prescribing information for complete boxed warning. • Severe and sometimes fatal hepatotoxicity has occurred in clinical trials. (5.1) •Monitor hepatic function prior to and during treatment. (5.1) • Interrupt and then reduce or discontinue STIVARGA for function tests or hepatocellular necrosis, depending upon severity and ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
pp.jazzpharma.comSee Full Prescribing Information for complete dosing instructions (2.1-2.7). Dosage for Adult Patients with Narcolepsy • Initiate dosage at 4.5 g per night orally, divided into two doses (2.1). • Titrate to effect in increments of up to 1.5 g per night per week (2.1). • Recommended dosage range: 6 g to 9 g per night orally, divided into two
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.cimzia.comSee full prescribing information for complete boxed warning. o Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to